The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rivoltini, L.
Right arrow Articles by Appella, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rivoltini, L.
Right arrow Articles by Appella, E.

The Journal of Immunology, Vol 154, Issue 5 2257-2265, Copyright © 1995 by American Association of Immunologists

ARTICLES

Induction of tumor-reactive CTL from peripheral blood and tumor- infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1

L Rivoltini, Y Kawakami, K Sakaguchi, S Southwood, A Sette, PF Robbins, FM Marincola, ML Salgaller, JR Yannelli and E Appella
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

MART-1 is an Ag expressed on melanomas and melanocytes, and is recognized by the majority of HLA-A2-restricted tumor-specific tumor- infiltrating lymphocytes (TIL) from melanoma patients. In the present study we have analyzed 10 potential 9-mer epitopes containing the HLA- A2.1 binding motifs for their ability to induce melanoma-specific T cell lines. Antimelanoma CTL could be generated only with MART-1(27-35) peptide, which has been previously shown to be recognized by a majority of HLA-A2-restricted TIL. Anti-MART-1(35-43)-specific CTL could also be induced, but these T cells did not recognize melanoma cells. MART-1(27- 35)-specific CTL could be effectively generated from a total of 11 of 12 PBL and from 3 of 3 TIL derived from HLA-A2+ melanoma patients, as well as from 2 of 4 PBL from HLA-A2+ healthy donors by in vitro stimulation with autologous PBMC pulsed with the synthetic MART-1(27- 35) peptide. These CTL lines specifically lysed and release cytokines (TNF-alpha, IFN-gamma, and GM-CSF) in response to T2 cells pulsed with MART-1(27-35), as well as to HLA-A2+ MART-1+ melanoma cells. CTL generated with MART-1(27-35) also lysed uncultured HLA-A2+ melanoma cells derived from tumor biopsies, indicating that this MART-1 epitope is likely to be expressed in association with HLA-A2 on the surface of tumor cells in vivo. CTL lines generated with MART-1(27-35) mediated 25- to 100-fold higher lytic activity than MART-1-reactive CTL grown from TIL in the presence of high dose IL-2. These results demonstrate that MART-1(27-35) peptide may represent an ideal candidate for Ag-specific immunotherapy in melanoma patients.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. Wang, S. Selleri, and F. M. Marincola
The Requirements for CTL-Mediated Rejection of Cancer in Humans: NKG2D and Its Role in the Immune Responsiveness of Melanoma
Clin. Cancer Res., December 15, 2007; 13(24): 7228 - 7231.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Derre, M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Levy, and D. E. Speiser
A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide
J. Immunol., December 1, 2007; 179(11): 7635 - 7645.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
Q.-S. Du, Y.-T. Wei, Z.-W. Pang, K.-C. Chou, and R.-B. Huang
Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction
Protein Eng. Des. Sel., September 1, 2007; 20(9): 417 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba, T. Krausz, R. Jagadeeswaran, and R. Salgia
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
Clin. Cancer Res., April 1, 2007; 13(7): 2246 - 2253.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials
J. Immunol., February 15, 2007; 178(4): 1975 - 1979.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Valenti, V. Huber, P. Filipazzi, L. Pilla, G. Sovena, A. Villa, A. Corbelli, S. Fais, G. Parmiani, and L. Rivoltini
Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-{beta}-Mediated Suppressive Activity on T Lymphocytes.
Cancer Res., September 15, 2006; 66(18): 9290 - 9298.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Zhang, A. Barber, and C. L. Sentman
Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor
Cancer Res., June 1, 2006; 66(11): 5927 - 5933.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Di Pucchio, L. Pilla, I. Capone, M. Ferrantini, E. Montefiore, F. Urbani, R. Patuzzo, E. Pennacchioli, M. Santinami, A. Cova, et al.
Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-{alpha} Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors.
Cancer Res., May 1, 2006; 66(9): 4943 - 4951.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli
Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity.
Cancer Res., April 15, 2006; 66(8): 4450 - 4460.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Pilla, P. Squarcina, J. Coppa, V. Mazzaferro, V. Huber, D. Pende, C. Maccalli, G. Sovena, L. Mariani, C. Castelli, et al.
Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96
Cancer Res., May 1, 2005; 65(9): 3942 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura
Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice
Clin. Cancer Res., December 15, 2004; 10(24): 8630 - 8640.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. PURI, M. S. ELLER, H. R. BYERS, S. DYKSTRA, J. KUBERA, and B. A. GILCHREST
Telomere-based DNA damage responses: a new approach to melanoma
FASEB J, September 1, 2004; 18(12): 1373 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang and F. G. Haluska
Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways
J. Immunol., April 1, 2004; 172(7): 4599 - 4608.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Rivoltini, C. Castelli, M. Carrabba, V. Mazzaferro, L. Pilla, V. Huber, J. Coppa, G. Gallino, C. Scheibenbogen, P. Squarcina, et al.
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells
J. Immunol., October 1, 2003; 171(7): 3467 - 3474.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Mehrotra, R. Stevens, R. Zengou, N. G. Chakraborty, L. H. Butterfield, J. S. Economou, D. I. Dorsky, and B. Mukherji
Regulation of Melanoma Epitope-specific Cytolytic T Lymphocyte Response by Immature and Activated Dendritic Cells, in Vitro
Cancer Res., September 1, 2003; 63(17): 5607 - 5614.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Tahara, K. Fujio, Y. Araki, K. Setoguchi, Y. Misaki, T. Kitamura, and K. Yamamoto
Reconstitution of CD8+ T Cells by Retroviral Transfer of the TCR {alpha}{beta}-Chain Genes Isolated from a Clonally Expanded P815-Infiltrating Lymphocyte
J. Immunol., August 15, 2003; 171(4): 2154 - 2160.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Parmiani, L. Pilla, C. Castelli, and L. Rivoltini
Vaccination of patients with solid tumours
Ann. Onc., June 1, 2003; 14(6): 817 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. G. Carrabba, C. Castelli, M. J. Maeurer, P. Squarcina, A. Cova, L. Pilla, N. Renkvist, G. Parmiani, and L. Rivoltini
Suboptimal Activation of CD8+ T Cells by Melanoma-derived Altered Peptide Ligands: Role of Melan-A/MART-1 Optimized Analogues
Cancer Res., April 1, 2003; 63(7): 1560 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
P. J. Durda, I. S. Dunn, L. B. Rose, D. Butera, E. M. Benson, F. Pandolfi, and J. T. Kurnick
Induction of "Antigen Silencing" in Melanomas by Oncostatin M: Down-Modulation of Melanocyte Antigen Expression
Mol. Cancer Res., April 1, 2003; 1(6): 411 - 419.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Mandruzzato, E. Rossi, F. Bernardi, V. Tosello, B. Macino, G. Basso, V. Chiarion-Sileni, C. R. Rossi, C. Montesco, and P. Zanovello
Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient
J. Immunol., October 1, 2002; 169(7): 4017 - 4024.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska
Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity
J. Immunol., July 1, 2002; 169(1): 531 - 539.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Monsurro, D. Nagorsen, E. Wang, M. Provenzano, M. E. Dudley, S. A. Rosenberg, and F. M. Marincola
Functional Heterogeneity of Vaccine-Induced CD8+ T Cells
J. Immunol., June 1, 2002; 168(11): 5933 - 5942.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
I. Prabakaran, C. Menon, S. Xu, A. Gomez-Yafal, B. J. Czerniecki, and D. L. Fraker
Mature CD83+ Dendritic Cells Infected With Recombinant gp100 Vaccinia Virus Stimulate Potent Antimelanoma T Cells
Ann. Surg. Oncol., May 1, 2002; 9(4): 411 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. K. Egilmez, S. D. Hess, F.-A. Chen, H. Takita, T. F. Conway, and R. B. Bankert
Human CD4+ Effector T Cells Mediate Indirect Interleukin-12- and Interferon-{gamma}-dependent Suppression of Autologous HLA-negative Lung Tumor Xenografts in Severe Combined Immunodeficient Mice
Cancer Res., May 1, 2002; 62(9): 2611 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
D Jager, E Jager, and A Knuth
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer
J. Clin. Pathol., September 1, 2001; 54(9): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Luft, M. Rizkalla, T. Y. Tai, Q. Chen, R. I. MacFarlan, I. D. Davis, E. Maraskovsky, and J. Cebon
Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation
J. Immunol., September 1, 2001; 167(5): 2529 - 2537.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Kurnick, T. Ramirez-Montagut, L. A. Boyle, D. M. Andrews, F. Pandolfi, P. J. Durda, D. Butera, I. S. Dunn, E. M. Benson, S. J. P. Gobin, et al.
A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter
J. Immunol., August 1, 2001; 167(3): 1204 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P.-Y. Dietrich, P. R. Walker, A.-L. Quiquerez, G. Perrin, V. Dutoit, D. Liénard, P. Guillaume, J.-C. Cerottini, P. Romero, and D. Valmori
Melanoma Patients Respond to a Cytotoxic T Lymphocyte-defined Self-Peptide with Diverse and Nonoverlapping T-Cell Receptor Repertoires
Cancer Res., March 1, 2001; 61(5): 2047 - 2054.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
P. J. Frost, L. H. Butterfield, V. B. Dissette, J. S. Economou, and B. Bonavida
Immunosensitization of Melanoma Tumor Cells to Non-MHC Fas-Mediated Killing by MART-1-Specific CTL Cultures
J. Immunol., March 1, 2001; 166(5): 3564 - 3573.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Valmori, V. Dutoit, V. Rubio-Godoy, C. Chambaz, D. Liénard, P. Guillaume, P. Romero, J.-C. Cerottini, and D. Rimoldi
Frequent Cytolytic T-Cell Responses to Peptide MAGE-A10254-262 in Melanoma
Cancer Res., January 1, 2001; 61(2): 509 - 512.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
P. R. Dunbar, C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, et al.
A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response
J. Immunol., December 1, 2000; 165(11): 6644 - 6652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Mitchell, J. Kan-Mitchell, B. Minev, C. Edman, and R. J. Deans
A Novel Melanoma Gene (MG50) Encoding the Interleukin 1 Receptor Antagonist and Six Epitopes Recognized by Human Cytolytic T Lymphocytes
Cancer Res., November 1, 2000; 60(22): 6448 - 6456.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
U. S. Kammula, F. M. Marincola, and S. A. Rosenberg
Real-Time Quantitative Polymerase Chain Reaction Assessment of Immune Reactivity in Melanoma Patients After Tumor Peptide Vaccination
J Natl Cancer Inst, August 16, 2000; 92(16): 1336 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. S. Bergmann-Leitner and S. I. Abrams
Differential Role of Fas/Fas Ligand Interactions in Cytolysis of Primary and Metastatic Colon Carcinoma Cell Lines by Human Antigen-Specific CD8+ CTL
J. Immunol., May 1, 2000; 164(9): 4941 - 4954.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Gervois, N. Labarriere, S. Le Guiner, M.-C. Pandolfino, J.-F. Fonteneau, Y. Guilloux, E. Diez, B. Dreno, and F. Jotereau
High Avidity Melanoma-reactive Cytotoxic T Lymphocytes Are Efficiently Induced from Peripheral Blood Lymphocytes on Stimulation by Peptide-pulsed Melanoma Cells
Clin. Cancer Res., April 1, 2000; 6(4): 1459 - 1467.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
D. Valmori, F. Levy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Lienard, V. Cerundolo, J.-C. Cerottini, and P. Romero
Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue
J. Immunol., January 15, 2000; 164(2): 1125 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. C. Panelli, A. Riker, U. Kammula, E. Wang, K.-H. Lee, S. A. Rosenberg, and F. M. Marincola
Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases
J. Immunol., January 1, 2000; 164(1): 495 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
D. Valmori, J.-F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar, D. Lienard, D. Rimoldi, V. Cerundolo, F. Jotereau, J.-C. Cerottini, et al.
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues
Int. Immunol., December 1, 1999; 11(12): 1971 - 1980.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Gomi, M. Nakao, F. Niiya, Y. Imamura, K. Kawano, S. Nishizaka, A. Hayashi, Y. Sobao, K. Oizumi, and K. Itoh
A Cyclophilin B Gene Encodes Antigenic Epitopes Recognized by HLA-A24-Restricted and Tumor-Specific CTLs
J. Immunol., November 1, 1999; 163(9): 4994 - 5004.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter
Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo
Cancer Res., October 1, 1999; 59(19): 4955 - 4963.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Wang, E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber
Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma
Clin. Cancer Res., October 1, 1999; 5(10): 2756 - 2765.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. Anichini, A. Molla, R. Mortarini, G. Tragni, I. Bersani, M. Di Nicola, A. M. Gianni, S. Pilotti, R. Dunbar, V. Cerundolo, et al.
An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CTL)-defined, Melanocyte-specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-specific CTLs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions
J. Exp. Med., September 6, 1999; 190(5): 651 - 668.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
M. J. Pittet, D. Valmori, P. R. Dunbar, D. E. Speiser, D. Lienard, F. Lejeune, K. Fleischhauer, V. Cerundolo, J.-C. Cerottini, and P. Romero
High Frequencies of Naive Melan-A/MART-1–specific CD8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (HLA)-A2 Individuals
J. Exp. Med., September 6, 1999; 190(5): 705 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Yang, M. Nakao, S. Shichijo, T. Sasatomi, H. Takasu, H. Matsumoto, K. Mori, A. Hayashi, H. Yamana, K. Shirouzu, et al.
Identification of a Gene Coding for a Protein Possessing Shared Tumor Epitopes Capable of Inducing HLA-A24-restricted Cytotoxic T Lymphocytes inCancer Patients
Cancer Res., August 1, 1999; 59(16): 4056 - 4063.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. M. Clay, M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura
Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity
J. Immunol., July 1, 1999; 163(1): 507 - 513.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Men, I. Miconnet, D. Valmori, D. Rimoldi, J.-C. Cerottini, and P. Romero
Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice
J. Immunol., March 15, 1999; 162(6): 3566 - 3573.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Yee, P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg
Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers
J. Immunol., February 15, 1999; 162(4): 2227 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. M. Clay, M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura
Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue
J. Immunol., February 1, 1999; 162(3): 1749 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
I. V. Redchenko and A. B. Rickinson
Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells
J. Virol., January 1, 1999; 73(1): 334 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Rivoltini, P. Squarcina, D. J. Loftus, C. Castelli, P. Tarsini, A. Mazzocchi, F. Rini, V. Viggiano, F. Belli, and G. Parmiani
A Superagonist Variant of Peptide MART1/Melan A27-35 Elicits Anti-Melanoma CD8+ T Cells with Enhanced Functional Characteristics: Implication for More Effective Immunotherapy
Cancer Res., January 1, 1999; 59(2): 301 - 306.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Valmori, N. Gervois, D. Rimoldi, J.-F. Fonteneau, A. Bonelo, D. Lienard, L. Rivoltini, F. Jotereau, J.-C. Cerottini, and P. Romero
Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide
J. Immunol., December 15, 1998; 161(12): 6956 - 6962.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. R. Reynolds, E. Celis, A. Sette, R. Oratz, R. L. Shapiro, D. Johnston, M. Fotino, and J.-C. Bystryn
HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients
J. Immunol., December 15, 1998; 161(12): 6970 - 6976.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. H. Butterfield, S. M. Jilani, N. G. Chakraborty, L. A. Bui, A. Ribas, V. B. Dissette, R. Lau, S. C. Gamradt, J. A. Glaspy, W. H. McBride, et al.
Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus
J. Immunol., November 15, 1998; 161(10): 5607 - 5613.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K.-H. Lee, M. C. Panelli, C. J. Kim, A. I. Riker, M. P. Bettinotti, M. M. Roden, P. Fetsch, A. Abati, S. A. Rosenberg, and F. M. Marincola
Functional Dissociation Between Local and Systemic Immune Response During Anti-Melanoma Peptide Vaccination
J. Immunol., October 15, 1998; 161(8): 4183 - 4194.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Rivoltini, M. Radrizzani, P. Accornero, P. Squarcina, C. Chiodoni, A. Mazzocchi, C. Castelli, P. Tarsini, V. Viggiano, F. Belli, et al.
Human Melanoma-Reactive CD4+ and CD8+ CTL Clones Resist Fas Ligand-Induced Apoptosis and Use Fas/Fas Ligand-Independent Mechanisms for Tumor Killing
J. Immunol., August 1, 1998; 161(3): 1220 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Bettinotti, C. J. Kim, K.-H. Lee, M. Roden, J. N. Cormier, M. Panelli, K. K. Parker, and F. M. Marincola
Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy
J. Immunol., July 15, 1998; 161(2): 877 - 889.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. F. Yoong, G. McNab, S. G. Hubscher, and D. H. Adams
Vascular Adhesion Protein-1 and ICAM-1 Support the Adhesion of Tumor-Infiltrating Lymphocytes to Tumor Endothelium in Human Hepatocellular Carcinoma
J. Immunol., April 15, 1998; 160(8): 3978 - 3988.
[Abstract] [Full Text] [PDF]

Home page